Clinical judgment, applied where the capital actually moves.

Dustin Stevenson, D.O.

Dustin Stevenson is a board-certified hematologist/oncologist with more than fifteen years of clinical experience spanning academic medicine, military medicine, and institutional cancer-center leadership, including prior roles as a hospital Department Chair and Cancer Committee Chairman.

Today his clinical work is structured as independent contract hematology/oncology coverage, run through his own practice entity. Stevenson HemOnc Advisors grew out of a simple observation from that vantage point: the people pricing small-cap hematology/oncology equities are almost never the people who can actually evaluate whether a trial's design supports the label its sponsor is promising, or whether a Phase 2 signal is durable enough to survive a randomized Phase 3.

Alongside his clinical background, Dustin has pursued formal coursework in financial accounting and business fundamentals — the layer that turns a clinical read into a usable one for anyone trying to underwrite risk in this sector. That combination — real bench-and-bedside oncology judgment plus fluency in a balance sheet, a cap table, and a cash-runway calculation — is what the firm sells.

Positive data doesn't matter if the company can't fund its way to the finish line. Negative data doesn't always mean what the stock price says it means. Both of those require reading the same document twice — once as a clinician, once as an analyst.

How the firm works

Stevenson HemOnc Advisors is intentionally a single-physician practice. There is no junior analyst translating a question up a chain, and no generalist healthcare coverage stretched thin across therapeutic areas outside hematology and oncology. Engagements are scoped narrowly — a specific trial, a specific readout, a specific diligence question — and delivered directly.